- |||||||||| HS-20094 / Jiangsu Hansoh Pharma
Efficacy and Safety of HS-20094 in Patients with Type 2 Diabetes (Exhibit Hall (West A1-A3) ePoster Theater A; 733) - May 20, 2024 - Abstract #ADA2024ADA_2297;
P2a
Patients with T2DM poorly controlled with diet and exercise alone or with stable metformin (HbA1c ?7.0 to ?10.0%) were randomly (4:1:1) assigned within each cohort to receive HS-20094 (5mg, 10mg or 15mg), semaglutide (1.0mg), or placebo subcutaneously once-weekly... In patients with T2DM, HS-20094 was generally safe and showed meaningful HbA1c, fasting blood glucose and body weight reductions.
- |||||||||| HS-20094 / Jiangsu Hansoh Pharma
Efficacy and Safety of HS-20094 in Patients with Type 2 Diabetes (Poster Hall (West A4-B2); 733) - May 20, 2024 - Abstract #ADA2024ADA_1855;
P2a
Patients with T2DM poorly controlled with diet and exercise alone or with stable metformin (HbA1c ?7.0 to ?10.0%) were randomly (4:1:1) assigned within each cohort to receive HS-20094 (5mg, 10mg or 15mg), semaglutide (1.0mg), or placebo subcutaneously once-weekly... In patients with T2DM, HS-20094 was generally safe and showed meaningful HbA1c, fasting blood glucose and body weight reductions.
- |||||||||| HS-20094 / Jiangsu Hansoh Pharma
Enrollment open: A Study of HS-20094 in Healthy Participants (clinicaltrials.gov) - Jul 19, 2022
P1, N=68, Recruiting,
In patients with T2DM, HS-20094 was generally safe and showed meaningful HbA1c, fasting blood glucose and body weight reductions. Not yet recruiting --> Recruiting
|
